Table 2 Early AD phenotype across genotype groups defined by APOE4 and BCHE-K carrier status

Sex

Female

75%

64%

50%

40%

29%

Onset of AD

Age-at-AD diagnosis (yrs)

60.8^a (4.4)

60.6^a1 (6.1)

67.0^b1 (4.0)

63.9 (7.6)

62.8 (7.8)

Age-at-baseline (yrs)

62.0^a (4.8)

62.1^a2 (5.9)

68.3^b2 (4.0)

64.8 (7.3)

64.4 (6.6)

Time since AD diagnosis at baseline (yrs)

1.2^a (1.2)

1.5^b (1.3)

1.3^a (1.2)

0.9^a (0.7)

1.6^b (1.9)

Neuroimaging

Hippocampal vol., % of ICV

0.26^a (0.05)

0.26^a (0.05)

0.24^a (0.03)

0.28^b (0.02)

0.28^b (0.03)

Ventricular vol., % of ICV

1.8^a (0.73)

2.9^a (1.54)

2.8^b (1.23)

2.3^b (0.97)

2.9^a (1.15)

CSF markers

Aβ₄₂, pg/mL

554^a (111)

641^a (139)

676^a (193)

755^b (195)

831^b (176)

p-tau₁₈₁, pg/mL

34.0^b (11.8)

40.4^a (12.2)

38.7^b (14.8)

42.5^a (15.8)

40.4^a (13.5)

NfL, pg/mL

1003^b (265)

1392^a (498)

1222^b (395)

1316^b (160)

1458^a (366)

Ng, pg/mL

493^b (188)

568^a (188)

506^b (257)

540^a (245)

515^b (247)

YKL-40, ng/mL

190^b (86.0)

247^b (143.3)

247^b (85.0)

351^a (164.5)

293^a (168.5)

Cognition

MMSE Total (0–30)

24.3^b (2.5)

23.8^b (2.5)

23.5^a (2.3)

23.4^a (2.4)

23.9^b (2.3)

MMSE Memory (0–6)

4.0^a (1.4)

3.9^a (1.0)

4.1^a (1.1)

4.2^a (1.3)

4.9^b (1.2)

MMSE Visual Construction (0–1)

0.8^b (0.5)

0.7^b (0.5)

0.7^b (0.5)

0.8^b (0.4)

0.3^a (0.5)

RBANS Total (40–160)

72.8^b (8.3)

65.5^a (10.5)

67.5^b (12.4)

72.0^b (13.4)

66.0^a (11.8)

RBANS Delayed Memory (40–154)

56.0^a (19.3)

52.7^a (13.7)

47.8^a (5.9)

69.0^b (26.2)

64.3^b (21.5)

RBANS Visuospatial/Constructional (40–154)

101.8^b (28.8)

90.4^b (25.6)

85.4^b (19.8)

79.4^a (21.1)

80.3^a (23.9)